Sinopharm Group

Sinopharm Group
Company typepublic
unlisted(A share)
SEHK: 1099(H share)
ISINCNE100000FN7
IndustryPharmaceutical
Founded
  • 1998 (predecessor)
  • 2003
FounderChina National Pharmaceutical Group
HeadquartersSinopharm Plaza, ,
China
Area served
China
Key people
  • Wei Yulin (Chairman)
  • Chen Qiyu (Vice-Chairman)
  • Li Zhiming (President)
Revenue CN¥227.069 billion (2015)
CN¥9.169 billion (2015)
CN¥3.761 billion (2015)
Total assets CN¥138.267 billion (2015)
Total equity CN¥30.052 billion (2015)
OwnerSinopharm Industrial Investment (56.79%)
ParentSinopharm Industrial Investment
SubsidiariesSinopharm CNMC
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards
Sinopharm Group Co., Ltd.
Simplified Chinese国药控股股份有限公司
Traditional Chinese國藥控股股份有限公司
Literal meaningSinopharm Holding Joint-Stock Limited Company
Transcriptions
Sinopharm Group
Simplified Chinese国药控股
Traditional Chinese國藥控股
Literal meaningSinopharm Holding
Transcriptions
Second alternative Chinese name
Simplified Chinese国控股份有限公司
Traditional Chinese國控股份有限公司
Transcriptions

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.

Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.